Sequence information
DRAVP ID DRAVPc015
Name Interferon alfa-n1
Sequence
Molecular Formula C860H1353N227O255S9
Condition/Disease HIV infection
Group Phase â…¡clinical trial
Type Protein
Description Interferon alfa-n1 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. It consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Active sequence/Structure
External Links
DrugBank Accession Number DB00011
Pubchem ID 46506227
CHEMBL ID CHEMBL2108509
UNII 41697D4Z5C
CAS 74899-72-2
Reference Not Available
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT00001113 | A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma | Human Immunodeficiency Virus (HIV) Infections Treatment | Completed | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000725 | A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma | Human Immunodeficiency Virus (HIV) Infections Treatment | Completed | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002086 | A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of | Human Immunodeficiency Virus (HIV) Infections Treatment | Completed | Phase 2 | Glaxo Wellcome |
